CAS: 54856-23-4; N-Methyl-2-(Pyridin-2-yl)Ethan-1-Amine Dimethanesulfonate

该化合物是一种该化合物是一种主要用作外皮抑制剂以管理梅涅雷病和相关脊椎紊乱的类苯胺.该化合物是H1受体的局部吸附剂和H3受体的对立剂,改善了可凝胶血液流动,减少了内分泌压力.该物质在水中的高溶性可以确保有利的生物利用率,而其稳定的晶体系结构允许在平板或可注射的形式上进行一致的配方.乙胺丙烯色色色的毒性较低,并且受到很好的调试,因此它成为长期治疗外膜功能失调的可靠治疗选择.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-11046978-B2
    优先权日:2016-03-16
    标 题:Synthesis of isoprenoids and derivatives
    发明人:GONZALEZ RAMON; CLOMBURG JAMES M; CHEONG SEOKJUNG
    权利人:UNIV RICE WILLIAM M
    摘要:This disclosure generally relates to the use of enzyme combinations or recombinant microbes comprising same to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds. Novel metabolic pathways exploiting Claisen, aldol, and acyioin condensations are used instead of the natural mevalonate (MVA) pathway or 1-deoxy-d-xylulose 5-phosphate (DXP) pathways for generating isoprenoid precursors such as isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), and geranyl pyrophosphate (GPP). These pathways have the potential for better carbon and or energy efficiency than native pathways. Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups. Isoprenoid alcohols are key intermediary products for the production of isoprenoid precursors in these novel synthetic metabolic pathways.

    专利号:WO-9946236-A1
    优先权日:1998-03-12
    标题 :Modulators of protein tyrosine phosphatases (ptpases)
    发明人:RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
    权利人:NOVO NORDISK AS; ONTOGEN CORP
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:EP-1062199-A1
    优先权日:1998-03-12
    标题 :Modulators of protein tyrosine phosphatases (ptpases)
    发明人:RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOLLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
    权利人:NOVO NORDISK AS; ONTOGEN CORP
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:US-5574824-A
    优先权日:1994-04-11
    标题 :Analysis/synthesis-based microphone array speech enhancer with variable signal distortion
    发明人:SLYH RAYMOND E; MOSES RANDOLPH L; ANDERSON TIMOTHY R
    权利人:US ARMY
    摘要:A microphone array speech enhancement algorithm based on analysis/synthesis filtering that allows for variable signal distortion. The algorithm is used to suppress additive noise and interference. The processing structure consists of delaying the received signals so that the desired signal components add coherently, filtering each of the delayed signals through an analysis filter bank, summing the corresponding channel outputs from the sensors, applying a gain function to the channel outputs, and combining the weighted channel outputs using a synthesis filter. The structure uses two different gain functions, both of which are based on cross correlations of the channel signals from the two sensors. The first gain yields the GEQ-I array, which performs best for the case of a desired speech signal corrupted by uncorrelated white background noise. The second gain yields the GEQ-II array, which performs best for the case where there are more signals than microphones. The GEQ-II gain allows for a trade-off on a channel-dependent basis of additional signal degradation in exchange for additional noise and interference suppression.

    专利号:US-2024182932-A1
    优先权日:2016-03-16
    标 题:Synthesis of isoprenoids and derivatives

    专利号:CA-2428283-C
    优先权日:2000-11-13
    标题 :Processes for continuous synthesis of polymer compositions as well as use of same
    常州市新力医药化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sinlypharm.com
    电话: 0519-86608206👤
    📞常州市新力医药化工有限公司 ⚠️参考联系方式

    销售电话:0519-86608206
    邮箱:shiyuhongapi@gmail.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    河南普瑞制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.puruipharm.com
    企业联系电话:0394-2531682;方小姐15618978166;郜运平13353857966;刘经理17796518191👤
    📞河南普瑞制药有限公司 ⚠️参考联系方式

    电话:0394-2531682;方小姐15618978166;郜运平13353857966;刘经理17796518191
    手机:方小姐15618978166;郜运平13353857966;刘经理17796518191
    传真:0394-2296661
    邮箱:purui888@163.com
    通信地址: 河南省西华县城叶庄桥
    邮编: 466600
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河南省西华县城叶庄桥
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    1. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database Syst Rev. 2016 Jun 21;2016(6):CD010696. doi: 10.1002/14651858.CD010696.pub2. 2. Ramos Alcocer R, Ledezma Rodríguez JG, Navas Romero A, Cardenas Nuñez JL, Rodríguez Montoya V, Deschamps JJ, Liviac Ticse JA. Use of betahistine in the treatment of peripheral vertigo. Acta Otolaryngol. 2015;135(12):1205-11. doi: 10.3109/00016489.2015.1072873. Epub 2015 Aug 6. BEMED Study Group. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016 Jan 21;352:h6816. doi: 10.1136/bmj.h6816.

    合成参考文献


    摘要:Drugs in Japan, 6(750), 1982
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知